IM Ketorolac vs Cambia for the Acute Treatment of Severe Migraine

Status unconfirmed · Phase 4 · Has a placebo group

Conditions studied: Migraine Headache

In brief

This research will be conducted to see if the oral drug Cambia is as effective in relieving severe migraine headaches as the injectable drug ketorolac.

Key facts

Study ID

NCT02664116

Run by

Scripps Health

People needed

40

Starts

2016-01-01

Expected to finish

2017-07-01

Last updated by the study team

2016-02-03

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients who meet IHS criteria for migraine
• Age 18 to 65
• At least 2 migraine attacks per month
• Able to give written consent
• Willing to complete the entire course of the study
• Current headache duration greater than or equal to 36 hours

You may not qualify if…

• Pregnant or nursing
• Significant medical or psychiatric disease
• History of gastritis, gastric ulcer, GI bleed
• Renal insufficiency
• Hepatic insufficiency
• History of opioid dependence within the last 10 years or currently
• Any current or prior use of DICLOFENAC POTASSIUM POWDER FOR ORAL SOLUTION (CAMBIA)
• Past allergic reaction to DICLOFENAC or other NSAIDs

Where it is running

• Scripps Clinic — La Jolla, California, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.